The role of let-7b in the inhibition of hepatic stellate cell activation by rSjP40.

BACKGROUND: Hepatic stellate cells (HSCs) are one of the main cell types involved in liver fibrosis induced by many factors, including schistosomes. Previous studies in our lab have shown that recombinant P40 protein from Schistosoma japonicum (rSjP40) can inhibit HSC activation in vitro. Let-7b is a member of the let-7 microRNA family and plays an inhibitory role in a variety of diseases and inflammatory conditions. In this study, we investigated the role of let-7b in the inhibition of HSC activation by rSjP40. METHODS: Expression of let-7b was detected by quantitative real-time PCR. A dual luciferase assay was used to confirm direct interaction between let-7b and collagen I. We also used western blot to assess protein levels of TGFßRI and collagen type I α1 (COL1A1). RESULTS: We found that rSjP40 up-regulates expression of let-7b in HSCs. Let-7b inhibits collagen I expression by directly targeting the 3'UTR region of the collagen I gene. Furthermore, we discovered that let-7b inhibitor partially restores the loss of collagen I expression caused by rSjP40. CONCLUSION: Our research clarifies the role of let-7b in the inhibition of HSC activation by rSjP40 and will provide new insights and ideas for the inhibition of HSC activation and treatment of liver fibrosis.

DFseq: Distribution-Free Method to Detect Differential Gene Expression for RNA-Sequencing Data.

Many current RNA-sequencing data analysis methods compare expressions one gene at a time, taking little consideration of the correlations among genes. In this study, we propose a method to convert such an one-dimensional comparison approach into a two-dimensional evaluation of the ratio of standard deviations (SD) of two constructed random variables. This method allows the identification of differentially expressed genes while controlling a preset significance level conditional on the read count mean-variance relationship. Meanwhile, correlations among genes are naturally accommodated due to the clustering of genes with similar distribution in the proposed σ-σ plot. The proposed distribution-free method is designated as DFseq, because it does not depend on a parametric distribution to fit read count. As a result, compared with parametric methods, DFseq can effectively handle genes with a bimodal-like distribution and/or genes with excessive 0 read counts, as well as genes with outlying observations. Besides, DFseq is an ideal platform for comparing performance of different differential gene expression detection methods.

Prior non-irradiative focal therapies do not compromise the efficacy of delayed episcleral plaque brachytherapy in retinoblastoma.

BACKGROUND/AIMS: Non-irradiative local therapies have shown promise in delaying or supplanting external beam radiotherapy (EBRT) and enucleation in patients with retinoblastoma. We hypothesised that prior focal therapy does not compromise the efficacy of delayed episcleral plaque brachytherapy (epBRT). METHODS: We performed an institutional review board-approved medical record review of patients with retinoblastoma who were treated with I-125 epBRT prior to (primary) or following chemoreduction (delayed), alone and in combination with non-irradiative focal therapy. Clinical and treatment characteristics were retrieved. Treatment failure was defined as the need for subsequent EBRT and/or enucleation. Event-free and ocular survival rates were calculated from the date of plaque placement. The cumulative incidences (CIs) of treatment failure and enucleation were compared across strata using Gray's test. RESULTS: We identified 50 patients with retinoblastoma (54 eyes), who received a total of 56 plaques between January 1986 and December 2010, with a median follow-up of 8.3 years (range, 0.8-21.2 years). The median time from diagnosis to plaque placement was 12.7 months (range, 0.1-128 months). The CI and 95% CI of treatment failure and enucleation following epBRT at 5 years was 37%±7.2% and42.2%±7.3%, respectively. The lack of prior diode or green laser therapy was predictive of increased risk for treatment failure (p=0.02 and 0.03). International Classification group C or D was predictive of decreased time to enucleation (p=0.004). The use of any focal therapy was not predictive of time to treatment failure (p=0.33). CONCLUSIONS: The use of non-irradiative focal therapies prior to or following epBRT does not decrease the time to enucleation or treatment failure.